Mirion Technologies, Inc. engages in the provision of radiation safety, science, and medicine. The company is headquartered in Atlanta, Georgia and currently employs 2,860 full-time employees. The company went IPO on 2020-06-29. The firm's segments include Nuclear & Safety and Medical. The Medical includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For Nuclear Power Plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).
The most recent EPS for Mirion Technologies Inc is $0.1, beating expectations of $0.09.
How did Mirion Technologies Inc MIR's revenue perform in the last quarter?
Mirion Technologies Inc revenue for the last quarter is $0.1
What is the revenue estimate for Mirion Technologies Inc?
According to 10 of Wall street analyst, the revenue estimate of Mirion Technologies Inc range from $294.0M to $266.56M
What's the earning quality score for Mirion Technologies Inc?
Mirion Technologies Inc has a earning quality score of B+/57.693394. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Mirion Technologies Inc report earnings?
Mirion Technologies Inc next earnings report is expected in 2026-07-27
What are Mirion Technologies Inc's expected earnings?
Mirion Technologies Inc expected earnings is $247.22M, according to wall-street analysts.
Did Mirion Technologies Inc beat earnings expectations?
Mirion Technologies Inc recent earnings of $257.6M beat expectations.